semaglutide soul Oral Gets FDA Approval for CV Event Reduction in High-risk Diabetes Patients SOUL trial shows oral semaglutide
Description
This is the most serious warning from the Food and Drug Administration (FDA)
Lee, S., & Lee, D
Semaglutide was linked to fewer user-initiated boluses at all follow-ups
Why are compounded GLP-1 products a concern
The timing of combining both therapies varies based on individual circumstances
Key Findings / Developments 6.3
